Recent News

Predicting Lung Cancer Response to Immunotherapy With Multimodal Genomic Features

Pembrolizumab Plus NK-Cell Therapy for Advanced Lung Cancer

Novel Assay Is Focus of Drug Screening Research in Resistant Lung Cancer

Bispecific Antibody Granted FDA Breakthrough Therapy Designation for Exon 20–Mutated NSCLC

Can Influenza Vaccines Trigger Immune Response in Patients With Lung Cancer?

FDA Accepts Biologics License Application for Proposed Biosimilar to Bevacizumab

Physical Activity and Quality of Life After Radiation Therapy for Lung Cancer

Brigatinib Granted FDA Priority Review for ALK-Positive Metastatic NSCLC

Atezolizumab Receives FDA Priority Review in NSCLC

ASCO-SITC 2020: HLA Expression in Primary Lung Tumors and Brain Metastases

MET Inhibitor Capmatinib Granted FDA Priority Review in Advanced Lung Cancer

ASCO–SITC 2020: Interim Trial Results With Pepinemab/Avelumab in Advanced NSCLC

ASCO-SITC 2020: Radiation Recall Pneumonitis and Nivolumab for Lung Cancer

Priority Review of Selpercatinib in RET-Driven Lung Cancer Granted by FDA

STS 2020: Intraoperative Molecular Imaging During Surgery for NSCLC

Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer

PET Imaging of Mitochondrial Activity in Lung Tumor Cells

FLAURA Trial: Overall Survival With Osimertinib in EGFR-Mutated Lung Cancer

Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?

ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer

RSNA 2019: Deep Learning Tool and Cardiovascular Health on Lung Cancer Screenings

Atezolizumab/Chemotherapy Approved by FDA in First-Line Treatment of Metastatic Lung Cancer

Case Studies: Possible Link Between Nivolumab for Lung Cancer and Pericardial Effusion

Final Overall Survival With Atezolizumab/Chemotherapy in Advanced Lung Cancer

Early Study Findings With Novel KRAS Inhibitor in Advanced Lung Cancers

SITC 2019: Atezolizumab Monotherapy Versus Chemotherapy in PD-L1–Selected Lung Cancer

ASCEND-7: Ceritinib for Brain Metastases From ALK-Positive Lung Cancer

3-Year Survival Update of KEYNOTE-024: Comparison of Pembrolizumab and Chemotherapy

Prognostic Indicators Among Patients With EGFR-Positive NSCLC

Investigational Drug Under Study in KRAS G12C–Mutant Lung Cancer

Mutations Linked to Poorer Outcomes in Lung Cancer Identified in MYSTIC Trial

ESMO 2019: Tissue Tumor Mutational Burden and Survival With Pembrolizumab in Lung Cancer

ASCO Breakthrough 2019: Lung Cancer Diagnosis Tool Takes CAD to New Dimensions

ESMO 2019: Liquid Biopsy May Guide Therapy for Some Patients With Lung Cancer

First-in-Human Trial of Anti-AXL Antibody-Drug Conjugate in Advanced Lung Cancer

ESMO 2019: First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC

WCLC 2019: Comparison of Screening Methods for Those at Risk of Lung Cancer

WCLC 2019: Blood Biomarker–Based Lung Cancer Screening